-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 27, Hengrui Pharmaceuticals issued an announcement stating that the company received the approval of the State Food and Drug Administration for the "Drug Supplementary Application Approval Notice" for remazolam tosylate for injection, in the 36mg specification that has been approved for marketing [ On the basis of remazolam {C21H19BrN4O2}], a new 25mg specification [calculated as remazolam {C21H19BrN4O2}] is added
In December 2019, the company's 36mg remazolam tosylate for injection [calculated as remazolam {C21H19BrN4O2}] was approved by the National Food and Drug Administration for routine gastroscopy sedation; it was approved for use in June 2020 Sedation of colonoscopy
Remazolam tosylate belongs to the class of benzodiazepines and is a short-acting GABAa receptor agonist
Remazolam besylate developed by PAIONAG, Germany, was approved for general anesthesia in Japan in January 2020, approved for procedural sedation in the United States in July 2020, and approved for listing in China in July 2020 Used for sedation during colonoscopy
Up to now, the total R&D expenses of remazolam tosylate for injection have been about 108.
